A
PHAT icon

Abingworth’s Phathom Pharmaceuticals PHAT Stock Holding History

Abingworth’s Portfolio PHAT Stock Details PHAT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		$16.1M Hold
1,435,106
– – 5.25% 6
2022
Q3 		$15.9M Hold
1,435,106
– – 5.44% 6
2022
Q2 		$12.1M Hold
1,435,106
– – 3.88% 6
2022
Q1 		$19.5M Buy
1,435,106
+231,971
+19% +$3.75M 5.53% 6
2021
Q4 		$23.6M Hold
1,203,135
– – 5.72% 6
2021
Q3 		$38.5M Hold
1,203,135
– – 8.74% 5
2021
Q2 		$40.7M Hold
1,203,135
– – 12.59% 2
2021
Q1 		$45.1M Hold
1,203,135
– – 15.56% 2
2020
Q4 		$40M Hold
1,203,135
– – 13.67% 3
2020
Q3 		$44.5M Hold
1,203,135
– – 9.52% 3
2020
Q2 		$39.4M Hold
1,203,135
– – 11.01% 3
2020
Q1 		$30.8M Hold
1,203,135
– – 20.47% 2
2019
Q4 		$37.4M Buy
+1,203,135
New +$30.2M 18.09% 2

Other funds holding PHAT

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $53.7B AUM 29.47% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GKIM
GW&K Investment Management Boston, Massachusetts $11.3B AUM 31.98% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return

Abingworth's PHAT Position: Q4 2022 in Review

Abingworth held its Phathom Pharmaceuticals (PHAT) position steady in Q4 2022 at 1,435,106 shares worth $16.1M. The position accounts for 5.25% of the portfolio, ranked #6.

Abingworth first reported a position in PHAT in Q4 2019 and has held it in 13 quarters since. The position peaked at $45.1M in Q1 2021. 87 funds tracked by Wall St. Rank hold PHAT as of Q4 2022.

  • Abingworth held 1,435,106 shares of Phathom Pharmaceuticals worth $16.1M as of Q4 2022.
  • Abingworth left its Phathom Pharmaceuticals share count unchanged in Q4 2022.
  • Phathom Pharmaceuticals made up 5.25% of Abingworth's portfolio in Q4 2022, its #6 holding.
  • Abingworth first reported a position in Phathom Pharmaceuticals in Q4 2019 and has held it in 13 quarters since.
  • Abingworth's Phathom Pharmaceuticals position peaked at $45.1M in Q1 2021.
  • 87 funds tracked by Wall St. Rank held Phathom Pharmaceuticals as of Q4 2022.

Based on Abingworth's 13F filing for Q4 2022, filed 10 Feb 2023.